On October 21, 2019 INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate Pharma" or the "Company"), a French biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need, reported the closing of its previously announced global offering to specified categories of investors of an aggregate of 14,375,000 new ordinary shares, comprising an offer of 9,922,227 ordinary shares in the form of American Depositary Shares ("ADSs"), each representing one ordinary share, in the United States at an offering price of $5.50 per ADS (the "U.S. Offering"), and a concurrent private placement of 4,452,773 ordinary shares in Europe (including France) and other countries outside of the United States at the corresponding offering price of €4.97 per ordinary share (the "European Private Placement," and together with the U.S. Offering, the "Global Offering") (Press release, Innate Pharma, OCT 21, 2019, View Source [SID1234542380]). Aggregate gross proceeds of the Global Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately $79.1 million (€71.4 million*). All of the ADSs and ordinary shares in the Global Offering were offered by Innate.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Innate Pharma’s ordinary shares are listed on Euronext Paris under the symbol "IPH" and its ADSs are listed on the Nasdaq Global Select Market under the symbol "IPHA". The ADSs began trading on the Nasdaq Global Select Market on October 17, 2019.
Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group LLC acted as joint bookrunners for the U.S. Offering and Citigroup acted as global coordinator for the European Private Placement. Namsen Capital acted as capital markets advisor to the Company.
A registration statement relating to these securities, including a prospectus, was declared effective by the U.S. Securities and Exchange Commission ("SEC") on October 16, 2019. The registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.